Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility

doi:10.2196/resprot.7289

JMIR Publications

JMIR Research Protocols

Browse by Year:

Browse:
Issues
Authors
Themes

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.

JMIR Research Protocols

Published on 20.03.17 in Vol 6, No 3 (2017): March

This paper is in the following e-collection/theme issue:

Tweetations for "Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility"

Bin Li, Steven A Eschrich, Anders Berglund, Melissa Mitchell, David Fenstermacher, Hadi Danaee, Hongyue Dai, Daniel Sullivan, William L Trepicchio, William S Dalton

JMIR Res Protoc 2017 (Mar 20); 6(3):e45

Tweets 1 - 2 of 2.

Tweets 1 - 2 of 2. 1

JMIR Research Protocols

Citing this Article

Published on 20.03.17 in Vol 6, No 3 (2017): March

This paper is in the following e-collection/theme issue:

Tweetations for "Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility"

Tweets 1 - 2 of 2.